Broadwood buys 570K Insight Molecular Diagnostics shares
Insight Molecular Diagnostics Inc. insider Broadwood Partners, L.P., together with related entities, reported net open-market purchases of 570,184 shares of IMDX common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Insight Molecular Diagnostics Inc. insider Broadwood Partners, L.P., together with related entities, reported net open-market purchases of 570,184 shares of IMDX common stock. The buys occurred between April 23 and April 27 in multiple tranches at weighted average prices around $3.50–$3.64 per share.
After these transactions, entities associated with Neal C. Bradsher report holding 12,684,884 shares of common stock, plus warrants currently exercisable for a total of 300,186 additional shares at an exercise price of $30.60 per share that expire on April 19, 2027.
Insider Trade Summary
Net Buyer: 570,184 shares
Net Buy
9 txns
Insider
BROADWOOD PARTNERS, L.P., BROADWOOD CAPITAL INC, Bradsher Neal C
Role
10% Owner | 10% Owner | 10% Owner
Bought
570,184 shs ($2.03M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock, no par value | 250,923 | $3.6391 | $913K |
| Purchase | Common Stock, no par value | 0 | $0.00 | $0.00 |
| Purchase | Common Stock, no par value | 38,880 | $3.5258 | $137K |
| Purchase | Common Stock, no par value | 0 | $0.00 | $0.00 |
| Purchase | Common Stock, no par value | 280,381 | $3.5025 | $982K |
| Purchase | Common Stock, no par value | 0 | $0.00 | $0.00 |
| holding | Warrant to Purchase Common Stock | -- | -- | -- |
| holding | Warrant to Purchase Common Stock | -- | -- | -- |
| holding | Common Stock, no par value | -- | -- | -- |
Holdings After Transaction:
Common Stock, no par value — 12,685,041 shares (Direct);
Common Stock, no par value — 12,684,884 shares (Indirect, Footnote);
Warrant to Purchase Common Stock — 150,093 contracts (Direct);
Warrant to Purchase Common Stock — 150,093 contracts (Indirect, Footnote)
Footnotes (6)
- F1. The reported securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. ("Broadwood Capital"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- F2. These securities are directly owned by Neal C. Bradsher.
- F3. This constitutes the weighted average purchase price. The prices range from $3.39 to $3.54. The Reporting Person will provide upon request by the Securities and Exchange Commission staff (the "SEC Staff"), the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- F4. This constitutes the weighted average purchase price. The prices range from $3.47 to $3.59. The Reporting Person will provide upon request by the SEC Staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- F5. This constitutes the weighted average purchase price. The prices range from $3.50 to $3.84. The Reporting Person will provide upon request by the SEC Staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- F6. These warrants are currently exercisable.
Key Figures
Net shares purchased: 570,184 shares
Purchase price 23 Apr: $3.5025 per share
Purchase price 24 Apr: $3.5258 per share
+5 more
8 metrics
Net shares purchased
570,184 shares
Net open-market buys across April 23–27 transactions
Purchase price 23 Apr
$3.5025 per share
Weighted average purchase price on April 23
Purchase price 24 Apr
$3.5258 per share
Weighted average purchase price on April 24
Purchase price 27 Apr
$3.6391 per share
Weighted average purchase price on April 27
Common shares after trades
12,684,884 shares
Total common stock reported following April 27 purchases
Warrant coverage
300,186 shares
Underlying IMDX common shares for reported warrants
Warrant exercise price
$30.60 per share
Exercise price for warrants expiring April 19, 2027
Warrant expiration
April 19, 2027
Expiration date for currently exercisable warrants
Key Terms
open-market purchase, weighted average purchase price, warrants, pecuniary interest, +1 more
5 terms
open-market purchase financial
"transaction_action": "open-market purchase""
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
weighted average purchase price financial
"This constitutes the weighted average purchase price. The prices range"
The weighted average purchase price is the average cost per share you paid across multiple buys, calculated so larger purchases count more than smaller ones. Imagine buying apples at different prices: the overall price you effectively paid depends on how many apples you bought at each price. Investors use it to measure true cost basis, calculate gains or losses, decide when to sell, and manage taxes and portfolio performance.
warrants financial
"These warrants are currently exercisable."
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
pecuniary interest financial
"disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein"
Section 16 regulatory
"beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934"
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Broadwood Partners report in this Form 4 for Insight Molecular Diagnostics (IMDX)?
Broadwood Partners, L.P. and related entities reported net open-market purchases of 570,184 IMDX common shares. The transactions increased their reported holdings to 12,684,884 shares, plus warrants exercisable for 300,186 additional shares at a $30.60 exercise price expiring April 19, 2027.
What warrant holdings tied to IMDX stock are disclosed in this Form 4?
The filing discloses warrants to purchase a total of 300,186 IMDX common shares, split between direct and indirect holdings. These warrants are currently exercisable at an exercise price of $30.60 per share and are scheduled to expire on April 19, 2027, according to the footnotes.
How does the Form 4 describe beneficial ownership for the Broadwood IMDX position?
The Form 4 states IMDX securities are directly owned by Broadwood Partners, L.P., and may be deemed beneficially owned by Broadwood Capital and Neal C. Bradsher. Each reporting person disclaims beneficial ownership beyond its or his pecuniary interest in the securities, consistent with Section 16 guidance.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates